Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Open-label Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of ART5803 in Participants With Anti-NMDAR Encephalitis and AntiNMDAR Autoantibody-Associated Psychiatric Disease

NCT07093333 is registered in ClinicalTrials.gov with Arialys Australia Pty Ltd as lead sponsor.

NCT NCT07093333
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07093333 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Open-label Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of ART5803 in Participants With Anti-NMDAR Encephalitis and AntiNMDAR Autoantibody-Associated Psychiatric Disease
Lead sponsor
Arialys Australia Pty Ltd
Phase
Phase 2
Overall status
Recruiting
Start date
May 15, 2026
Completion date
May 30, 2028
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anti-n-methyl-d-aspartate receptor (nmdar) antibody-associated psychiatric disease, anti-n-methyl-d-aspartate receptor (nmdar) encephalitis (anre), autoimmune encephalitis